U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06865547) titled 'ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide' on Feb. 20.
Brief Summary: This is a Phase 4, multi-center, single arm, open-label clinical study to evaluate whether participants with mHSPC treated with apalutamide will benefit from the 4A ProActive Management Model.
The study will include a Screening Period of up to 14 days before assignment on Day 1 to establish study eligibility. Participants will get 4A ProActive Management according to the protocol .
As the background disease treatment, participants will received apalutamide according to local label (240 ...